Absci Corporation Collaborates with Invetx to Develop AI-Based Drug Creation Platform for Animal Health
Shots:
- Absci Corporation & Invetx have entered into a strategic collaboration to develop an innovative Half-Life Extension platform for animal health
- The alliance will leverage Absci’s generative AI models to develop modular antibody sequences in animals, while Invetx gains rights to use HLE platform for improving therapeutic effect duration & customer convenience of various products. The deal includes R&D funding, election fees, milestones & royalties on a per-product basis
- The goal is to address unmet needs in animal health, starting with canines and potentially expanding to other companion animals
Ref: Absci | Image: Absci & Invetx
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
